# reload+after+2024-01-20 16:43:28.155946
address1§Tuborg Boulevard 12
city§Hellerup
zip§2900
country§Denmark
phone§45 70 22 22 44
website§https://ascendispharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
fullTimeEmployees§797
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Jan Moller Mikkelsen', 'age': 63, 'title': 'President, CEO, Member of Executive Board & Executive Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Scott T. Smith', 'age': 49, 'title': 'CFO, Executive VP & Member of Executive Board', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lotte  Sonderbjerg', 'age': 62, 'title': 'Executive VP, Chief Administrative Officer & Member of the Executive Board', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael Wolff Jensen L.L.M.', 'age': 52, 'title': 'Executive VP, Chief Legal Officer & Member of the Executive Board', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Peter  Rasmussen', 'age': 54, 'title': 'VP of Finance & Principal Accounting Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Timothy J. Lee', 'title': 'Senior Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Flemming Steen Jensen', 'age': 62, 'title': 'Executive Vice President of Product Supply & Quality - Endocrinology Rare Diseases', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Kennett  Sprogoe Ph.D.', 'age': 44, 'title': 'Executive Vice President of Research & Product Development', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stina  Singel M.D., Ph.D.', 'age': 49, 'title': 'Executive VP & Head of Clinical Development for Oncology', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joseph  Kelly', 'age': 54, 'title': 'Head of U.S. Commercial of Endocrinology', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.53
priceToSalesTrailing12Months§48.326748
currency§USD
dateShortInterest§1702598400
forwardEps§-0.02
exchange§NMS
quoteType§EQUITY
shortName§Ascendis Pharma A/S
longName§Ascendis Pharma A/S
firstTradeDateEpochUtc§1422455400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§68400868-eb49-3e91-a1a2-ed438c4632e5
gmtOffSetMilliseconds§-18000000
targetHighPrice§0.49
targetLowPrice§0.2
targetMeanPrice§0.33
targetMedianPrice§0.29
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§2.376
grossMargins§0.80219
ebitdaMargins§0.0
trailingPegRatio§None
